Terms ending in 2035
Every in-force patent on Glytec, LLC's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,897,565 | System and Method for Optimizing Insulin Dosages for Diabetic Subjects In force · High confidence | Glytec, LLC | In force | High confidence | |
| US 11,311,213 | Insulin Management In force · High confidence | Glytec, LLC | In force | High confidence | |
| US 9,892,234 | Subcutaneous Outpatient Management In force · High confidence | Glytec, LLC | In force | High confidence | |
| US 10,128,002 | Subcutaneous Outpatient Management In force · Medium confidence | Glytec, LLC | In force | Medium confidence | |
| US 10,403,397 | Subcutaneous Outpatient Management In force · Medium confidence | Glytec, LLC | In force | Medium confidence | |
| US 11,678,800 | Subcutaneous Outpatient Management In force · High confidence | Glytec, LLC | In force | High confidence | |
| US 11,694,785 | A Method and Dosing Controller for Subcutaneous Outpatient Management In force · Medium confidence | Glytec, LLC | In force | Medium confidence | |
| US 12,023,127 | Subcutaneous Outpatient Management In force · Medium confidence | Glytec, LLC | In force | Medium confidence | |
| US 12,620,473 | A Method and Dosing Controller for Adminstering a Correction Dose of Insulin In force · Medium confidence | Glytec, LLC | In force | Medium confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.